Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
Takeda Pharmaceutical has sealed a partnership pact with PRA Health Sciences under which the US CRO will serve as a primary strategic partner for the Japanese drug major’s clinical development and post-approval needs, the two companies said on September 13.…
To read the full story
Related Article
- As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
- Takeda’s R&D Organization Rejig Making Steady Headway as a Whole
February 2, 2017
- Takeda to Revamp R&D Organization, Eyes Consolidated Research Sites in Japan, US
August 1, 2016
BUSINESS
- Nippon Kayaku’s Avastin Biosimilar Share Hits 58%
February 3, 2026
- Japan’s 1st OTC Morning-After Pill Now Available
February 3, 2026
- Amgen Ends Rocatinlimab Pact with Kyowa Kirin
February 3, 2026
- AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
- Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…